Investors Should Know: A major Phase 3 trial win from Moderna ( MRNA) and Merck ( MRK) has sent ripple effects across the ...

A top Barclays biopharma analyst says the forces that froze biotech dealmaking are breaking apart, and the pharma giants ...

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3% ...

CEOs in any industry face certain challenges around innovating. In biotechnology, these problems can lead to projects being ...

Investors might want to bet on Moleculin Biotech, Inc. (MBRX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

PBE concentrates on 31 companies and offers a higher dividend yield, while IBBQ spreads risk across 251 holdings at a ...

WHX to take place from 25–28 January 2027 across Dubai Exhibition Centre, Expo City and Dubai World Trade Centre By ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering ...

Gaps are information. They are the place on the chart where you can see buyers and sellers jumping ahead to a fast repricing, ...

FTC challenges Amgen's Enbrel patent strategy, the long, winding path for the Moderna-Merck cancer vaccine, and more biotech ...

North Carolina’s life sciences industry has grown to include 860 companies statewide that employ 76,000 North Carolinians, ...